Pre-Open Stock Movers 02/22: (MTOR) (VEV) (HMHC) Higher; (FIXX) (KPTI) (YNDX) Lower (more...)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Macy's (M) PT Lowered to $40 at Jefferies
February 23, 2022 7:44 AM ESTJefferies analyst Stephanie Wissink lowered the price target on Macy's (NYSE: M) to $40.00 (from $45.00) while maintaining a Buy rating following results.
The analyst commented, "M beat Q4, guided FY22 above the Street, and issued 3YR targets of +LSD% sales growth and LDD% EBITDA... More
Karyopharm Therapeutics (KPTI) Wild Ride Occurring as M&A Speculation Proved Wrong Amid Executive Departure - RBC
February 22, 2022 12:40 PM ESTRBC Capital analyst Brian Abrahams weighed in on Karyopharm Therapeutics (NASDAQ: KPTI) amid the recent turbulence in the stock, including the 20% up move on Friday on the conference cancellation, which triggered M&A speculation, and today's 31% downdraft on the departure of CMO Dr. Jatin... More
Morgan Stanley Reiterates Equalweight Rating on Karyopharm Therapeutics (KPTI), 'lack of potential takeout news likely to disappoint'
February 22, 2022 10:33 AM ESTMorgan Stanley analyst Michael Ulz reiterated an Equalweight rating and $10.00 price target on Karyopharm Therapeutics (NASDAQ: KPTI).
The analyst comments "CMO departure surprising, but lack of potential takeout news likely to disappoint. This morning, Karyopharm announced several changes to the clinical leadership team. Most notable, Jatin Shah, EVP and CMO for the past 5 years, is leaving to pursue other opportunities... More
